Navigation Links
Cancer checkpoint
Date:4/5/2013

Healthy cells don't just happen. As they grow and divide, they need checks and balances to ensure they function properly while adapting to changing conditions around them.

Researchers studying a set of proteins that regulate physiology, caloric restriction and aging have discovered another important role that one of them plays. SIRT4, one of seven sirtuin proteins, is known for controlling fuel usage from its post in the mitochondria, the cell's energy source. It responds to stressful changes in the availability of nutrients for the cell.

New research reveals that SIRT4 is also extremely sensitive to a different form of stress: DNA damage. This unsuspected response by the metabolic checkpoint means SIRT4 doubles as a sentry guarding against cancer, which is spurred by genetic abnormalities.

Sirtuins have become familiar for their connection to longevity and to resveratrol, the red-wine compound that activates SIRT1, but less attention has been focused on SIRT3, SIRT 4 and SIRT5, all of which are found in mitochondria. Marcia Haigis, HMS associate professor of cell biology, led a team that has uncovered SIRT4 as an important player in the DNA damage response pathway, coordinating a sequence of events that normally result[s] in tumor suppression. They published their results April 4 in Cancer Cell.

"When we started studying SIRT4, we were focused only on its metabolic role, looking for functions related to diabetes and obesity," said Haigis. "What we found, to our surprise, was that SIRT4 was responsive to DNA damage, so that led us to investigate the metabolic response to DNA damage and how SIRT4 controls the metabolic response to genotoxic stress."

To see how SIRT4 normally functions, Haigis and her colleagues induced DNA damage by exposing cells in a lab dish to ultraviolet light. This damage triggered a halt in glutamine metabolism, limiting the amount of nutrients the cell could use as it goes through a cycle of division and growth.

Blocking the cell cycle at this juncture is important. If cell growth after DNA damage goes unchecked, proliferation of impaired cells can lead to cancer. When SIRT4 works properly, this chain of events is broken before bad cells and their abnormal genes multiply. SIRT4 blocks glutamine metabolism, arrests the cell cycle and suppresses tumor formation.

The scientists tested this SIRT4 response in mice. Bred to lack the gene that encodes the SIRT4 protein but otherwise normal, the mice spontaneously developed lung cancer by 15 months.

"When SIRT4 is missing, you don't have this metabolic checkpoint involving glutamine, which is important because glutamine is an amino acid required for proliferation in the cell," Haigis said. "Without SIRT4, the cell keeps dividing even in the face of DNA damage, so the cell accumulates more damage."

The scientists also analyzed data showing SIRT4 gene expression levels are low in several human cancers, including small-cell lung carcinoma, gastric cancer, bladder carcinoma, breast cancer and leukemia.

While they cannot say if SIRT4 loss alone will initiate cancer, its absence appears to create an environment in which tumor cells survive and grow.

"Our findings suggest that SIRT4 may be a potential target against tumors," they conclude.


'/>"/>

Contact: David Cameron
david_cameron@hms.harvard.edu
617-432-0441
Harvard Medical School
Source:Eurekalert

Related medicine news :

1. Voices Against Brain Cancer Responds to Research Identifying Contributing Factor in Brain Tumors
2. Lung Cancer Asbestos Victims Center Now Urges Victims Of Any Kind Of Lung Cancer Victim Who Were Exposed To Asbestos At Their Workplace To Call Them About Compensation
3. Moffitt Cancer Center researchers discuss new frontiers in breast cancer screening
4. Counting copy numbers characterises prostate cancer
5. Common Asphalt Sealant May Raise Cancer Risks
6. Cancer Patients May Be Unintended Victims of Budget Cuts
7. U.S. Spends More on Dementia Care Than Heart Disease or Cancer: Study
8. Prostate cancer treatment study changing the way doctors practice
9. Dementia costs top those for heart disease or cancer, study finds
10. Lung Cancer Asbestos Victims Center Now Urges Lung Cancer Victims To Contact Them About Possibly Significant Financial Compensation If They Were Exposed To Asbestos At Work
11. Intermittent Hormone Treatment for Prostate Cancer Not the Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
(Date:2/10/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... its growing list of Partner Firms. S.S. Nesbitt is headquartered in Birmingham, ... and in between. , Harnessing the experience and insights of the agency’s team ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a definitive agreement ... laboratory service centers across the country. Launched in April of 2015, Apifiny is the ... prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable ... find and select appointments via Everseat’s free mobile app. , The partnership gives ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... , Feb. 10, 2016 Mast ... developing novel, clinical-stage therapies for sickle cell disease and ... public offering of 29,090,910 units at a price to ... of one share of the Company,s common stock and ... common stock at an exercise price of $0.42 per ...
(Date:2/10/2016)... , Feb. 10, 2016 ALSP, Inc. announced ... MD as Consultant for Medical Affairs in preparation for its ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased to ... look forward to working with an individual of such practical ... look forward to drawing deeply on his broad experience and ...
Breaking Medicine Technology: